Grail's Galleri blood test shows promise in detecting early-stage cancers, boosting the company's stock, but experts call for more data before broad rollout.
Arch Capital's Q3 earnings beat expectations, driven by strong underwriting income and improved combined ratio, despite a decline in gross and net premiums written at the company level.
Interstellar comet 3I/ATLAS brightens rapidly, drawing interest from space agencies and amateur astronomers alike.
Grail's Galleri blood test shows promise in detecting early-stage cancers, boosting the company's stock, but experts call for more data before broad rollout.
Arch Capital's Q3 earnings beat expectations, driven by strong underwriting income and improved combined ratio, despite a decline in gross and net premiums written at the company level.
Interstellar comet 3I/ATLAS brightens rapidly, drawing interest from space agencies and amateur astronomers alike.